Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 22;11(9):e053336.
doi: 10.1136/bmjopen-2021-053336.

Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial

Affiliations

Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial

Carley Rusch et al. BMJ Open. .

Abstract

Introduction: Constipation is a common and sometimes debilitating non-motor symptom of Parkinson's disease (PD) that can result in intestinal inflammation and microbial dysbiosis. The Mediterranean diet, rich in fermentable fibres and anti-inflammatory phenolic compounds, is associated with reduced risk of developing PD and slower progression of parkinsonism. The Mediterranean diet is often recommended for people with PD; however, no studies to date examine this diet as a therapeutic intervention to modulate gastrointestinal (GI) dysfunction.

Methods and analysis: This is a randomised, controlled, parallel study. During a 2-week run-in, participants with PD and constipation symptoms (n=52) will undergo baseline nutritional and neurological assessments and provide a stool sample. Participants will be stratified by sex and Hoehn and Yahr stage and randomised to follow standard of care for constipation (control) or standard of care plus a Mediterranean diet (intervention) for 8 weeks. A study dietitian will provide dietary instruction and weekly follow-up via telephone to both groups to support adherence and monitor adverse events. Questionnaires will assess dietary intake and GI function including stool frequency, form, symptoms and laxative usage. Measurements completed at baseline will be repeated at 4 and 8 weeks of the intervention. The primary outcome is to evaluate the difference between mean change (final-baseline) in Gastrointestinal Symptom Rating Scale (GSRS) constipation syndrome scores for the control versus intervention groups. Secondary outcomes will assess stool frequency and form, weekly GSRS syndrome scores, digestive quality of life, laxative usage, faecal microbial communities and inflammatory markers, anxiety, depression, quality life, body weight and composition, dietary fibre intake and Mediterranean diet adherence.

Ethics and dissemination: The study has received University of Florida Institutional Review Board-01 approval (IRB202001333). Findings will be disseminated via conference presentations, lectures and peer-reviewed publications.

Trial registration number: NCT04683900.

Keywords: Parkinson's disease; functional bowel disorders; immunology; nutrition & dietetics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study design and participant flow. ASA-24, Automated Self-Administered 24-hour Dietary Assessment Tool; GSRS, Gastrointestinal Symptom Rating Scale; IC, informed consent; IE, inclusion and exclusion criteria; IPAQ, International Physical Activity Questionnaire.

References

    1. Hess CW, Okun MS. Diagnosing Parkinson disease. Continuum 2016;22:1047–63. 10.1212/CON.0000000000000345 - DOI - PubMed
    1. Kaye J, Gage H, Kimber A, et al. . Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006;21:1270–3. 10.1002/mds.20942 - DOI - PubMed
    1. Rahman S, Griffin HJ, Quinn NP, et al. . Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008;23:1428–34. 10.1002/mds.21667 - DOI - PubMed
    1. Fasano A, Visanji NP, Liu LWC, et al. . Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015;14:625–39. 10.1016/S1474-4422(15)00007-1 - DOI - PubMed
    1. Braak H, de Vos RAI, Bohl J, et al. . Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67–72. 10.1016/j.neulet.2005.11.012 - DOI - PubMed

Publication types

Associated data